β-casein nanovehicles for oral delivery of chemotherapeutic Drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells

Oncotarget

Volumn 7, Issue 17, 2016, Pages 23322-23334

  Bar Zeev, Maya ^a   Assaraf, Yehuda G ^a   Livney, Yoav D ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Gastric cancer; Multidrug resistance reversal; Paclitaxel tariquidar combination; Target activated oral delivery; casein micelles

Indexed keywords

BETA CASEIN; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; PACLITAXEL; TARIQUIDAR; ANTINEOPLASTIC AGENT; BETA CATENIN; CTNNB1 PROTEIN, HUMAN; DRUG CARRIER; MULTIDRUG RESISTANCE PROTEIN 1; NANOPARTICLE; QUINOLINE DERIVATIVE;

ARTICLE; BINDING KINETICS; BIOASSAY; CANCER RESISTANCE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG EFFICACY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MICELLE; MICROSCOPY; MULTIDRUG RESISTANCE; NANOPHARMACEUTICS; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PROTEIN EXPRESSION; SPECTROFLUOROMETRY; SPECTROPHOTOMETRY; STOICHIOMETRY; WESTERN BLOTTING; ZETA POTENTIAL; APOPTOSIS; CELL PROLIFERATION; CHEMISTRY; COMBINATION DRUG THERAPY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; STOMACH TUMOR; TUMOR CELL CULTURE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; ATP-BINDING CASSETTE, SUB-FAMILY B, MEMBER 1; BETA CATENIN; CELL PROLIFERATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; MICELLES; NANOPARTICLES; PACLITAXEL; QUINOLINES; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84966545879     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8019     Document Type: Article

References (58)

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64:252-271.
2. Nagini S. Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012; 4:156-169.
3. Shapira A, Assaraf YG, Livney YD. Beta-casein nanovehicles for oral delivery of chemotherapeutic drugs. Nanomedicine. 2010; 6:119-126.
4. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997; 15:110-115.
5. Ashour HM, El-Sharif A. Microbial spectrum and antibiotic susceptibility profile of gram-positive aerobic bacteria isolated from cancer patients. J Clin Oncol. 2007; 25: 5763-5769.
6. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resist Updates. 2011; 14:150-163.
7. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007; 26:153-181.
8. Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updates. 2012; 15:183-210.
9. Livney YD, Assaraf YG. Rationally designed nanovehicles to overcome cancer chemoresistance. Adv Drug Deliv Rev. 2013; 65:1716-1730.
10. Zhitomirsky B, Assaraf YG. Lysosomes as mediators of drug resistance in cancer. Drug Resist Updates. 2016; 24:23-33.
11. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5:219-234.
12. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990; 38:1277-1287.
13. Shukla S, Ohnuma S, Ambudkar SV. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets. 2011; 12:621-630.
14. Mei L, Zhang Z, Zhao L, Huang L, Yang XL, Tang J, Feng SS. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev. 2013; 65:880-890.
15. Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: A new platform for nanomedicine. Int J Pharm. 2009; 379:201-209.
16. Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Release. 2013; 170:15-40.
17. Livney YD, Schwan AL, Dalgleish DG. A Study of β-Casein Tertiary Structure by Intramolecular Crosslinking and Mass Spectrometry. J Dairy Sci. 2004; 87:3638-3647.
18. Mikheeva LM, Grinberg NV, Grinberg VY, Khokhlov AR, de Kruif CG. Thermodynamics of Micellization of Bovine β-Casein Studied by High-Sensitivity Differential Scanning Calorimetry. Langmuir. 2003; 19:2913-2921.
19. Shapira A, Assaraf YG, Epstein D, Livney YD. Betacasein Nanoparticles as an Oral Delivery System for Chemotherapeutic Drugs: Impact of Drug Structure and Properties on Co-assembly. Pharm Res. 2010; 27:2175-2186.
20. Shapira A, Markman G, Assaraf YG, Livney YD. β-casein-based nanovehicles for oral delivery of chemotherapeutic drugs: drug-protein interactions and mitoxantrone loading capacity. Nanomedicine. 2010; 6:547-555.
21. Shapira A, Davidson I, Avni N, Assaraf YG, Livney YD. β-Casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma: Stability, targetactivated release and cytotoxicity. Eur J Pharm Biopharm. 2012; 80:298-305.
22. Livney YD. Milk proteins as vehicles for bioactives. Curr Opin Colloid Interface Sci. 2010; 15:73-83.
23. Semo E, Kesselman E, Danino D, Livney YD. Casein micelle as a natural nano-capsular vehicle for nutraceuticals. Food Hydrocol. 2007; 21:936-942.
24. Haham M, Ish-Shalom S, Nodelman M, Duek I, Segal E, Kustanovich M, Livney YD. Stability and bioavailability of vitamin D nanoencapsulated in casein micelles. Food Funct. 2012; 3:737-744.
25. Benede S, Lopez-Exposito I, Gimenez G, Grishina G, Bardina L, Sampson HA, Molina E, Lopez-Fandino R. In vitro digestibility of bovine beta-casein with simulated and human oral and gastrointestinal fluids. Identification and IgE-reactivity of the resultant peptides. Food Chem. 2014; 143:514-521.
26. Journo-Gershfeld G, Kapp D, Shamay Y, Kopecek J, David A. Hyaluronan Oligomers-HPMA Copolymer Conjugates for Targeting Paclitaxel to CD44-Overexpressing Ovarian Carcinoma. Pharm Res. 2012; 29:1121-1133.
27. Iyer SS, Gao S, Zhang ZP, Kellogg GE, Karnes HT. A molecular model to explain paclitaxel and docetaxel sensitivity changes through adduct formation with primary amines in electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom. 2005; 19: 1221-1226.
28. Montagner IM, Banzato A, Zuccolotto G, Renier D, Campisi M, Bassi P, Zanovello P, Rosato A. Paclitaxelhyaluronan hydrosoluble bioconjugate: Mechanism of action in human bladder cancer cell lines. Urol Oncol-Semin O I. 2012.
29. Egusquiaguirre SP, Igartua M, Hernández RM, Pedraz JL. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol. 2012; 14:83-93.
30. Egger M, Li X, Müller C, Bernhardt G, Buschauer A, König B. Tariquidar Analogues: Synthesis by CuI-Catalysed N/O-Aryl Coupling and Inhibitory Activity against the ABCB1 Transporter. Eur J Org Chem. 2007; 2007:2643-2649.
31. Fox E, Bates SE. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther. 2007; 7:447-459.
32. Hendrikx JJ, Lagas JS, Wagenaar E, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. Br J Cancer. 2014; 110: 2669-2676.
33. Sarisozen C, Vural I, Levchenko T, Hincal AA, Torchilin VP. PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells. Drug deliv. 2012; 19:169-176.
34. Wang F, Zhang D, Zhang Q, Chen Y, Zheng D, Hao L, Duan C, Jia L, Liu G, Liu Y. Synergistic effect of folatemediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance. Biomaterials. 2011; 32:9444-9456.
35. Lakowicz JR. Principles of Fluorescence Spectroscopy. (New York, USA: Springer Science & Business Media). 2006.
36. Ferenc M, Pedziwiatr-Werbicka E, Nowak K, Klajnert B, Majoral J-P, Bryszewska M. Phosphorus Dendrimers as Carriers of siRNA-Characterisation of Dendriplexes. Molecules. 2013; 18:4451-4466.
37. Forrest SA, Yada RY, Rousseau D. Interactions of Vitamin D3 with Bovine β-Lactoglobulin A and β-Casein. J Agric Food Chem. 2005; 53:8003-8009.
38. Lietaer E, Poiffait A, Adrian J. Interaction between casein and vitamin A. Lebensm-Wiss Technol. 1991; 24:39-45.
39. Clark DC, Wilde PJ, Wilson DR, Wustneck R. The interaction of sucrose esters with β-lactoglobulin and β-casein from bovine milk. Food Hydrocol. 1992; 6:173-186.
40. Bachar M, Mandelbaum A, Portnaya I, Perlstein H, Even-Chen S, Barenholz Y, Danino D. Development and characterization of a novel drug nanocarrier for oral delivery, based on self-assembled β-casein micelles. J Control Release. 2012; 160:164-171.
41. Esmaili M, Ghaffari SM, Moosavi-Movahedi Z, Atri MS, Sharifizadeh A, Farhadi M, Yousefi R, Chobert J-M, Haertlé T, Moosavi-Movahedi AA. Beta casein-micelle as a nano vehicle for solubility enhancement of curcumin; food industry application. Lebensm-Wiss Technol. 2011; 44:2166-2172.
42. Yang FH, Zhang Q, Liang QY, Wang SQ, Zhao BX, Wang YT, Cai Y, Li GF. Bioavailability Enhancement of Paclitaxel via a Novel Oral Drug Delivery System: Paclitaxel-Loaded Glycyrrhizic Acid Micelles. Molecules. 2015; 20: 4337-4356.
43. Zhao YL, Li YL, Ge JJ, Li N, Li LB. Pluronic-poly (acrylic acid)-cysteine/Pluronic L121 mixed micelles improve the oral bioavailability of paclitaxel. Drug Dev Ind Pharm. 2014; 40:1483-1493.
44. Xu W, Fan X, Zhao Y, Li L. Cysteine modified and bile salt based micelles: Preparation and application as an oral delivery system for paclitaxel. Colloids Surf, B. 2015; 128:165-171.
45. Joshi N, Saha R, Shanmugam T, Balakrishnan B, More P, Banerjee R. Carboxymethyl-Chitosan-Tethered Lipid Vesicles: Hybrid Nanoblanket for Oral Delivery of Paclitaxel. Biomacromol. 2013; 14:2272-2282.
46. Battogtokh G, Ko Y. Self-assembled Chitosan-Ceramide Nanoparticle for Enhanced Oral Delivery of Paclitaxel. Pharm Res. 2014; 31:3019-3030.
47. Pandita D, Ahuja A, Lather V, Benjamin B, Dutta T, Velpandian T, Khar R. Development of Lipid-Based Nanoparticles for Enhancing the Oral Bioavailability of Paclitaxel. AAPS Pharm Sci Tech. 2011; 12:712-722.
48. Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticlemediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release. 2009; 136:21-29.
49. Jain S, Kumar D, Swarnakar NK, Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials. 2012; 33:6758-6768.
50. Jain S, Patil SR, Swarnakar NK, Agrawal AK. Oral Delivery of Doxorubicin Using Novel Polyelectrolyte-Stabilized Liposomes (Layersomes). Mol Pharm. 2012; 9:2626-2635.
51. Zambito Y, Felice F, Fabiano A, Di Stefano R, Di Colo G. Mucoadhesive nanoparticles made of thiolated quaternary chitosan crosslinked with hyaluronan. Carbohydr Polym. 2013; 92:33-39.
52. Puga AM, Lima AC, Mano JF, Concheiro A, Alvarez-Lorenzo C. Pectin-coated chitosan microgels crosslinked on superhydrophobic surfaces for 5-fluorouracil encapsulation. Carbohydr Polym. 2013; 98:331-340.
53. Patel NR, Rathi A, Mongayt D, Torchilin VP. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm. 2011; 416:296-299.
54. Portnaya I, Cogan U, Livney YD, Ramon O, Shimoni K, Rosenberg M, Danino D. Micellization of Bovine Beta Casein Studied by Isothermal Titration Microcalorimetry and Cryogenic Transmission Electron Microscopy. J Agric Food Chem. 2006; 54:5555-5561.
55. Eftink MR, Ghiron CA. Exposure of Tryptophanyl Residues in Proteins-Quantitative-Determination by Fluorescence Quenching Studies. Biochem. 1976; 15:672-680.
56. Penalva R, Esparza I, Agüeros M, Gonzalez-Navarro CJ, Gonzalez-Ferrero C, Irache JM. Casein nanoparticles as carriers for the oral delivery of folic acid. Food Hydrocol. 2015; 44:399-406.
57. Delgado AV, Gonzalez-Caballero E, Hunter RJ, Koopal LK, Lyklema J. Measurement and interpretation of electrokinetic phenomena-(IUPAC technical report). Pure Appl Chem. 2005; 77:1753-1805.
58. Washington N, Washington C, Wilson CG. Physiological Pharmaceutics. Biological Barriers to Drug Absorption. 2001; 75-103.